Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: January 28, 2026 JCR Pharmaceuticals Co., Ltd. [4552.T] TOKYO, Jan 28 (Pulse News Wire) – JCR Pharmaceuticals Co., Ltd. (4552) has revised its FY2026/3 Full-Year consolidated earnings forecast. AI-translated content. 🟡 Confidence: Standard See terms • Original filing 💬 Help us improve translation quality Notice any errors in this article? Let us know with one click. ⚠️ Report an error Please sign in to report errors 🎁 Report 3+ errors with your
Source disclosure: January 28, 2026
JCR Pharmaceuticals Co., Ltd. [4552.T]
TOKYO, Jan 28 (Pulse News Wire) – JCR Pharmaceuticals Co., Ltd. (4552) has revised its FY2026/3 Full-Year consolidated earnings forecast.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing